Literature DB >> 31395437

ROS1-rearranged NSCLC With Secondary Resistance Mutation: Case Report and Current Perspectives.

Florian Guisier1, Nicolas Piton2, Mathieu Salaun3, Luc Thiberville3.   

Abstract

Entities:  

Keywords:  Cabozantinib; Crizotinib; G2032R ROS1 mutation; ROS1 inhibitors; Secondary resistance mutation

Mesh：

Substances：

Year:  2019        PMID： 31395437     DOI： 10.1016/j.cllc.2019.06.007

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN： 1525-7304            Impact factor:   4.785


× No keyword cloud information.
  3 in total

1.  Correlating ROS1 Protein Expression With ROS1 Fusions, Amplifications, and Mutations.

Authors:  Richard S P Huang; Amanda Gottberg-Williams; Panhia Vang; Shoua Yang; Nicholas Britt; Jaspreet Kaur; James Haberberger; Natalie Danziger; Clarence Owens; Sara E Beckloff; Jeffrey S Ross; Shakti H Ramkissoon
Journal:  JTO Clin Res Rep       Date:  2020-09-18

Review 2.  Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations.

Authors:  Edouard Dantoing; Nicolas Piton; Mathieu Salaün; Luc Thiberville; Florian Guisier
Journal:  Int J Mol Sci       Date:  2021-06-11       Impact factor: 5.923

3.  Molecular and clinicopathological characteristics of ROS1-rearranged non-small-cell lung cancers identified by next-generation sequencing.

Authors:  Meiying Cui; Yuchen Han; Pan Li; Jianying Zhang; Qiuxiang Ou; Xiaoling Tong; Ruiying Zhao; Nan Dong; Xue Wu; Wencai Li; Guozhong Jiang
Journal:  Mol Oncol       Date:  2020-09-14       Impact factor: 7.449
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.